per Schedule M or WHO GMP. For foreign sponsors, local CMOs offer both trial supply manufacturing and regulatory interface support.

GMP Compliance and Quality Agreements

Per Schedule M of the Drugs and Cosmetics Act and ICH Q7/Q10 guidelines, Indian CMOs must adhere to Good Manufacturing Practices. The sponsor retains ultimate responsibility for ensuring that the contract facility operates under an approved quality system. A written Quality Agreement outlining roles for release, deviation handling, complaint management, and change control is mandatory.

Core Clinical Trial Insights

Site Qualification and Regulatory Licensing

Indian CMOs must obtain CDSCO approval under Rule 55 of the NDCTR to manufacture clinical trial materials. This involves submitting:

• Site Master File (SMF)
• Manufacturing and control protocols
• Quality system documentation
• Stability data if applicable
• Undertaking in Form CT-10

The Drugs Controller General of India (DCGI) may inspect the site before approval. Manufacturing without appropriate licensing can result in product seizure and trial suspension.

Technology Transfer and Scale-Up

Often, R&D-developed formulations must be transferred to the CDMO for GMP batch scale-up. This process includes:

• Technology transfer package (TTP) from sponsor
• Process validation protocols (PV protocol)
• Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs)

Both parties must align on material specifications, excipient grades, and analytical methods. Validation batches must be completed before trial supply release.

Packaging, Labeling, and Blinding Operations

CDMOs in India often handle trial-specific packaging including blinding, randomization code implementation, and temperature-sensitive labeling. NDCTR requires that labels bear the statement “For Clinical Trial Use Only” and other critical information like protocol number, batch number, expiry, and storage conditions. Temperature mapping of packaging areas is also mandatory.

Stability Testing and Shelf Life Assignment

If IMPs or placebos are stored for extended durations, the CMO must initiate ICH Q1A-compliant stability studies. Accelerated and long-term data should support the labeled expiry. In India, trial supply shelf life cannot exceed that supported by the available stability data at time of release.

Batch Record Review and Product Release

CMOs generate batch manufacturing records (BMRs) and batch packaging records (BPRs), which must be reviewed by QA and provided to the sponsor. Release is done only after:

• Completion of in-process and finished product testing
• Approval of Certificate of Analysis (CoA)
• Assessment of deviations and change controls
• Verification against protocol-specific requirements

Sponsor QA typically performs final IMP release or delegates Qualified Person (QP) responsibility as per EU/UK requirements.

Temperature-Controlled Storage and Logistics Support

Indian CMOs offer cold-chain solutions for biologics, vaccines, and thermolabile APIs. Warehouses are equipped with 21 CFR Part 11-compliant data loggers, remote alarms, and qualified HVAC systems. Trial shipments are typically dispatched with temperature monitoring devices and real-time tracking systems.

Documentation and Regulatory Traceability

All manufacturing and release documentation must be archived for at least 5 years (or per sponsor’s requirement) and made available for regulatory audits. This includes:

• Analytical test reports
• Cleaning validation records
• Deviation investigations
• Change control forms
• Sterility or endotoxin results for parenterals

Cross-referencing between clinical trial protocols and manufacturing documents is essential for regulatory traceability.

Audits, Inspections, and Regulatory Risk Management

Most reputed Indian CDMOs undergo regular audits by sponsors, WHO PQ teams, or EU/FDA inspectors. Risk-based audit programs assess:

• GMP and data integrity compliance
• CAPA implementation
• Contamination controls and OOS handling

Noncompliance may result in blacklisting of the site, import alerts, or invalidation of the clinical trial batch.

Best Practices & Preventive Measures

• Ensure upfront due diligence and audit of the CDMO before engagement
• Draft detailed technical and quality agreements covering full lifecycle
• Establish clear SOPs for deviation handling, recalls, and labeling errors
• Coordinate supply planning with trial enrollment to avoid wastage
• Use dual-release mechanisms (CDMO + Sponsor QA)

Scientific & Regulatory Evidence

• NDCTR 2019: Rules 52–61 govern manufacture of clinical trial supplies in India
• ICH Q10: Pharmaceutical Quality System principles for outsourced operations
• WHO GMP Annex 7: Guidelines on contract manufacturing
• Schedule M: Indian GMP standards for pharmaceutical manufacturing
• CDSCO Guidance on Clinical Trial Supply: CDSCO website, notifications 2019–2023

Special Considerations

Role of CDMOs in Adaptive and Decentralized Trials

With the rise of platform and basket trials in India, CDMOs are now offering on-demand packaging and supply chain tailoring based on interim analysis. For decentralized trials, blister-packed drugs may be directly shipped to patients via central depots following temperature mapping, courier tracking, and confirmation-of-receipt documentation.

Start-Up Biotech and CDMO Partnerships

Many early-phase biotech startups lack internal GMP capacity. CDMOs fill this gap by offering end-to-end support including formulation development, stability studies, CTM packaging, and regulatory dossier support. However, startups must still retain final responsibility for trial integrity and compliance.

When Sponsors Should Seek Regulatory Advice

• When using unlicensed CDMOs or foreign suppliers for trial supply
• To understand requirements for CT-10 license under NDCTR 2019
• Before changing CDMO mid-study (requires amendment and re-approval)
• For temperature excursion handling protocols in biologics trials
• To validate blinding, randomization, and labeling workflows

FAQs

1. Can an Indian CMO manufacture clinical trial supplies without CDSCO approval?

No. They must have a valid Form CT-10 manufacturing license and operate a GMP-compliant facility.

2. Who is responsible for trial drug release—CDMO or Sponsor?

Typically, the sponsor retains release authority. CDMOs may perform technical release, but final release rests with sponsor QA or Qualified Person (QP) where applicable.

3. What happens if there’s a deviation during manufacturing?

Deviations must be recorded, investigated, and assessed for impact on product quality. Sponsor must be notified, and CAPA initiated before release.

4. Is stability testing mandatory before trial initiation?

Stability data must support the proposed shelf life at time of batch release. Long-term studies may continue in parallel during the trial.

5. Do Indian CDMOs support blinding and labeling?

Yes. Most mid-to-large CDMOs offer secondary packaging, blinding, and labeling services with barcode integration and comparator handling.

6. Can CDMOs store trial supplies and ship globally?

Yes. With appropriate warehousing and export documentation, Indian CDMOs can distribute trial supplies globally—provided all regulatory and GMP conditions are met.

7. How long should CDMO records be retained?

All records should be retained for a minimum of 5 years post-study or as per sponsor-specific requirements.

Conclusion

Contract manufacturing in Indian clinical trials is no longer limited to cost efficiencies—it is a strategic enabler of speed, compliance, and scalability. With proper licensing, GMP adherence, and sponsor oversight, Indian CDMOs can significantly contribute to global drug development programs while aligning with CDSCO and international expectations. Sponsors must ensure robust due diligence, clear quality agreements, and strong monitoring to leverage the full potential of contract manufacturing in clinical research.